ALK maintains China bet despite geopolitical unrest
Front lines between China and the Western world have gotten more pronounced recently. Despite this, Danish allergy company ALK is ramping up its activities in the communist-ruled country with double-digit investments this year. ”China is a huge opportunity for us,” CEO Carsten Hellmann tells MedWatch.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
In recent times, a string of Danish life science firms has been worried over rising geopolitical tensions between Western countries and China.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK predicts 8–12 percent revenue growth in 2022
For subscribers
Global supply issues have ALK thinking creatively
For subscribers
